| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/21/1999 | US5955105 Stabilized thyroid hormone preparations and methods of making same |
| 09/21/1999 | US5955103 Dosage form comprising antiepileptic drug |
| 09/21/1999 | US5955101 Dry starch-iodine pharmaceutical formulations |
| 09/21/1999 | US5955100 Prodrugs their preparation and use as pharmaceuticals |
| 09/21/1999 | US5955098 C 3-8 linear or branched hydrocarbon propellant |
| 09/21/1999 | US5955097 Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
| 09/21/1999 | US5955091 Photobluing/whitening-resistant cosmetic/dermatological compositions comprising TiO2 pigments and deformable hollow particulates |
| 09/21/1999 | US5955086 Oregano for the treatment of internal parasites and protozoa |
| 09/21/1999 | US5955079 Composition comprising high molecular weight primary carrier, secondary carrier comprising t-dependent antigen conjugated to primary carrier, having enhanced antibody response to both carriers |
| 09/21/1999 | US5955059 Treating psoriasis, other skin disorders |
| 09/21/1999 | US5955058 Stabilized medicinal aerosol solution formulations containing ipratropium bromide |
| 09/21/1999 | CA2164513C Sustained release excipient |
| 09/21/1999 | CA2153543C Solvant rich gelled cosmetic and/or dermatologic composition containing hollow particles; uses thereof |
| 09/21/1999 | CA2101189C Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| 09/21/1999 | CA2030550C Very low temperature casting of controlled release microspheres |
| 09/16/1999 | WO1999046284A2 Molecules that home to various selected organs or tissues |
| 09/16/1999 | WO1999046283A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/16/1999 | WO1999046273A1 Composition containing a precursor capable of being hydrolysed by glucocerebrosidase |
| 09/16/1999 | WO1999046245A2 PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
| 09/16/1999 | WO1999045970A1 Multicomponent complex for use with a substrate |
| 09/16/1999 | WO1999045966A1 Polynucleotide composition, method of preparation, and use thereof |
| 09/16/1999 | WO1999045964A1 Poly(ethylene glycol) derivatives with proximal reactive groups |
| 09/16/1999 | WO1999045960A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | WO1999045953A1 Heparin cofactor ii-containing compositions and method for stabilizing the same |
| 09/16/1999 | WO1999045947A1 In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases |
| 09/16/1999 | WO1999045938A1 Thrombin preparation and products and fibrin sealant methods employing same |
| 09/16/1999 | WO1999045934A1 Bubbling enteric coated preparations |
| 09/16/1999 | WO1999045918A1 Methods and compositions for delivery of taxanes |
| 09/16/1999 | WO1999045903A1 Colonic delivery of protein or peptide compositions |
| 09/16/1999 | WO1999045896A1 Artificial nail compositions and related methods |
| 09/16/1999 | WO1999045895A1 Novel powder compositions |
| 09/16/1999 | WO1999045887A2 Monolithic tablet for controlled drug release |
| 09/16/1999 | WO1999045788A1 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 09/16/1999 | WO1999036059A3 Microcapsules; process for preparing microcapsules containing a biologically active compound and liquid solution |
| 09/16/1999 | WO1999033522A3 Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancer |
| 09/16/1999 | WO1999032082A3 Pharmaceutical compositions |
| 09/16/1999 | WO1996012802A9 Vaccine and antitoxin for treatment and prevention of c. difficile disease |
| 09/16/1999 | DE19910855A1 Composition comprising structured water with pharmaceutical or cosmetic use |
| 09/16/1999 | DE19810965A1 Nanoparticles comprising polyelectrolyte complex of polycation, polyanion and biologically active agent, especially useful for controlled drug release on oral administration |
| 09/16/1999 | CA2601285A1 Agents for use in the treatment of amyloidosis |
| 09/16/1999 | CA2588590A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/16/1999 | CA2587736A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/16/1999 | CA2323210A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 09/16/1999 | CA2323062A1 Colonic delivery of protein or peptide compositions |
| 09/16/1999 | CA2323016A1 Multicomponent complex for use with a substrate |
| 09/16/1999 | CA2322741A1 Thrombin preparation and products and fibrin sealant methods employing same |
| 09/16/1999 | CA2322232A1 Lyophilized polynucleotide composition, method of preparation, and uses thereof |
| 09/16/1999 | CA2321026A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/16/1999 | CA2288240A1 Methods and compositions for delivery of taxanes |
| 09/15/1999 | EP0942002A1 Iron-casein complex and process for preparing the same |
| 09/15/1999 | EP0941334A2 Protease-activatable pseudomonas exotoxin a-like proproteins |
| 09/15/1999 | EP0941315A1 Immune responses using compositions containing stress proteins |
| 09/15/1999 | EP0941125A1 Methods for regulating angiogenesis |
| 09/15/1999 | EP0941123A2 Delivery of nucleic acid material to target cells in biological systems |
| 09/15/1999 | EP0941122A2 Compositions and methods for polynucleotide delivery |
| 09/15/1999 | EP0941121A2 Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies |
| 09/15/1999 | EP0941120A1 Branched peptide linkers |
| 09/15/1999 | EP0941100A2 Pharmaceutical compositions containing lamivudine and zidovudine |
| 09/15/1999 | EP0941097A1 Use of mixtures of active substances for the production of hypocholesteremic agents |
| 09/15/1999 | EP0941095A1 Improved pharmaceutical compositions |
| 09/15/1999 | EP0941090A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 09/15/1999 | EP0941089A2 Compositions and methods for treating or preventing inflammatory diseases |
| 09/15/1999 | EP0941087A1 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections |
| 09/15/1999 | EP0941085A2 Formulation for electrically assisted delivery of lidocaine and epinephrine |
| 09/15/1999 | EP0941079A1 Bioceramic compositions |
| 09/15/1999 | EP0941075A1 Rapidly releasing and taste-masking pharmaceutical dosage form |
| 09/15/1999 | EP0941071A1 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| 09/15/1999 | EP0941070A2 Lozenge for the modified releasing of active substances in the gastrointestinal tract |
| 09/15/1999 | EP0941069A1 COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF |
| 09/15/1999 | EP0941068A1 Process for the preparation of a controlled release system |
| 09/15/1999 | EP0941039A1 Transdermal administration of ment |
| 09/15/1999 | EP0748383B1 Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences |
| 09/15/1999 | EP0652752B1 Water-dispersible tablets |
| 09/15/1999 | EP0644746B1 The use of glycerin in moderating transdermal drug delivery |
| 09/15/1999 | EP0627942B1 Improvements in or relating to contrast agents |
| 09/15/1999 | CN1228712A Aqueous-based pharmaceutical composition |
| 09/15/1999 | CN1228710A Pharmaceutical composition containing lornoxicam and disodic salt of EDTA |
| 09/15/1999 | CN1228708A Peptide-containing drug compositions for oral administration |
| 09/15/1999 | CN1228707A Titanium slow-release composition |
| 09/15/1999 | CN1228699A Antifungal composition with enhanced bioavailability |
| 09/15/1999 | CN1228692A Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
| 09/15/1999 | CN1228339A Sponge material capable of promoting spinal cord tissue wound healing, its preparing method and use |
| 09/15/1999 | CN1228338A Wound covering material capable of promoting wound healing |
| 09/14/1999 | US5952499 Therapeutic compound-fatty acid conjugates |
| 09/14/1999 | US5952387 Photostable aqueous solution containing benzyl alcohol derivatives |
| 09/14/1999 | US5952312 NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration |
| 09/14/1999 | US5952300 Antifungal compositions |
| 09/14/1999 | US5952232 Expandible microparticle intracellular delivery system |
| 09/14/1999 | US5952008 Desolventizing a solution with a pharmaceutically active polypeptide and an adjuvant for enhancing the systemic absorption of the peptide dissolved therein; pulverizing the dry solid, optionally agglomerating, loading into inhaler |
| 09/14/1999 | US5952006 Drug preparations for treating impotency |
| 09/14/1999 | US5952004 Emulsified drug delivery systems |
| 09/14/1999 | US5952000 Transdermal drug delivery system: an active pharmaceutical permeant in a penetration enhancing system of fatty acid esters of lactic acid salts such as sodium lauroyl lactylate and a pressure sensitive adhesive carrier vehicle |
| 09/14/1999 | US5951990 Ascorbyl-phosphoryl-cholesterol |
| 09/14/1999 | US5951981 Thrombolytic agents with antithrombotic activity |
| 09/14/1999 | US5951974 At least about 15%, preferably about 30%, of the interferon conjugates have a nonantigenic alkylpolyether attached to a preferential histidine residue; high activity; reacting an n-oxycarbonyloxyimide at acidic ph |
| 09/14/1999 | US5951972 Stabilization of somatotropins and other proteins by modification of cysteine residues |
| 09/14/1999 | US5951971 Eye-drops for treatment of eye disorders and surrounding area comprising cyclosporin and surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenol ether and polyoxyethylene alkyl ethers |
| 09/14/1999 | US5951962 Mesoporous silica, its preparation and its use |
| 09/14/1999 | CA2170869C Amine-derivatized nucleosides and oligonucleosides |
| 09/14/1999 | CA2071446C Synthetic catalytic oligonucleotide structures |